US Drug Watchdog Urges Transvaginal Mesh Failure Victims Who’ve Been Told There Are No More Fixes To Call Them For The Names Of Top Lawyers To Assist With Compensation

June 3, 2013

The US Drug Watchdog is urging women who have had what is called a unsuccessful revision surgery to repair a failed transvaginal mesh implant, and have now been told there is nothing more that can be done to call them for the names, and contacts of the nations top transvaginal mesh lawyers, who are passionate about doing their best to ensure every severely injured transvaginal mesh recipient gets the best possible financial compensation for their ordeal. For more information women, who are victims of a transvaginal mesh failure involving severe medical complications are urged to contact the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com

(PRWEB) June 03, 2013

The US Drug Watchdog is urging victims of a transvaginal mesh failure to call them immediately if they have had a unsuccessful revision surgery to repair the failure, and they are now being told there is nothing more that can be done for them, because the group believes these women need access to the nation’s leading transvaginal mash failure lawyers, who are extremely passionate about helping these individuals, and fighting for the best possible compensation. According to court records, “A transvaginal mesh failure occurs when the mesh fails to bind to a woman’s pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. This complication is more commonly referred to as “erosion.” The US Drug Watchdog’s initiative is designed to assist any women in the US, who is a victim of a transvaginal mesh failure involving the most severe medical complications, and the group is promising to provide these women with the names, and contacts for the nation’s leading transvaginal mesh lawyers. For more information women, who are now severely injured victims of a transvaginal mesh failure are urged to call the US Drug Watchdog anytime at 866-714-6466.

The US Drug Watchdog is indicating symptoms of a transvaginal mesh implant failure may include:

  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Vaginal Bleeding
  • Vaginal Infection
  • Urinary problems (constant UTI’s)
  • Organ perforation
  • Hardening of the vaginal mesh
  • Injury to nearby organs
  • Severe Pelvic Pain

The US Drug Watchdog says, “One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures involving medical devices like a transvaginal mesh failure. We need to emphasize severely injured transvaginal mesh recipients are in all US states, from Massachusetts, and all of New England, To New York, Florida, and all of the Atlantic Coast states, to Georgia, Alabama, and all of the Southeast states, to Ohio, and all Midwest states, to Kansas, and all of the Plains states, to Colorado and the Mountain West states, to California, and all of the Southwest, and Washington state, and all of the Northwest. If you have a friend, or loved one who is a recipient of a transvaginal mesh, tape, or sling type product that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain all women, who are transvaginal mesh failure victims with severe medical complications get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal.” http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multidistrict litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:

C.R. Bard, Inc., (MDL No. 2187);

American Medical Systems Inc., MDL No. 2325);

Boston Scientific Corp., (MDL No. 2326); and Johnson & Johnson’s Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10755987.htm

Source: prweb

comments powered by Disqus